Guska develops solutions based on synthetic RNA oncolytic virus therapy that have potent and safe immunostimulatory effects to address the pain point of cancer treatment by providing a targeted and less harmful alternative to traditional therapies.
Our technology uses synthetic RNA viruses designed to safely reach and destroy cancer cells without affecting normal cells and promoting a robust immune response against tumor cells.
Company Details
- Employees
- 10
- Founded
- -
- Address
- 2020 Mataojo, Montevideo,11400,uruguay
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://guska.bio/
- HQ
- Montevideo
Guska Questions
Guska's website is https://guska.bio/
Guska's LinkedIn profile is https://uy.linkedin.com/company/guska
Guska has
10 employees.
View email and phone details for 10
employees at Guska.
Guska's industry is
Biotechnology Research
Guska's top competitors are
Izi Park,
Locbio,
Bondum,
Xeptiva Therapeutics,
Polymera,
Otilia Ai, Maternidad Más Simple,
Atgen,
Lab+,
Rypto,
B4-Rna.
Guska's categories are Biotechnology Research
Guska's founding year is 2024
